Log in

LON:N4PN4 Pharma Share Price, Forecast & News

GBX 4.25
0.00 (0.00 %)
(As of 07/7/2020 05:01 AM ET)
Add
Compare
Today's Range
3.83
Now: GBX 4.25
4.40
50-Day Range
3.95
MA: GBX 4.69
6.10
52-Week Range
2
Now: GBX 4.25
7.90
Volume1.04 million shs
Average Volume1.76 million shs
Market Capitalization£6.47 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom. It reformulates marketed generic drugs; and improves delivery of novel and existing vaccines and therapeutics. The company is developing Sildenafil for use in treating erectile dysfunction; Sartans for the treatment of hypertension; Aprepitant for use in oncology and pain relief; and Aprepitant for the treatment of premature ejaculation. It is also developing Nuvec, an engineered silica nanoparticle for use in intracellular delivery of large nucleic acids, such as pDNA and mRNA; and Single dose Hepatitis B vaccine. The company has a research collaboration with MedImmune to explore the manufacture of a prototype nanomedicine using its Nuvec system. N4 Pharma Plc is based in London, the United Kingdom.
Read More
N4 Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1332-690061

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£23,524.00
Cash FlowGBX 1.08 per share
Book ValueGBX 1 per share

Profitability

Miscellaneous

Employees5
Market Cap£6.47 million
Next Earnings DateN/A
OptionableNot Optionable

Receive N4P News and Ratings via Email

Sign-up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter.

N4 Pharma (LON:N4P) Frequently Asked Questions

How has N4 Pharma's stock been impacted by COVID-19 (Coronavirus)?

N4 Pharma's stock was trading at GBX 2.75 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, N4P stock has increased by 54.5% and is now trading at GBX 4.25. View which stocks have been most impacted by Coronavirus.

How were N4 Pharma's earnings last quarter?

N4 Pharma PLC (LON:N4P) released its quarterly earnings data on Tuesday, February, 25th. The company reported ($0.87) earnings per share for the quarter. View N4 Pharma's earnings history.

Has N4 Pharma been receiving favorable news coverage?

News articles about N4P stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. N4 Pharma earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about N4 Pharma.

Who are some of N4 Pharma's key competitors?

What other stocks do shareholders of N4 Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other N4 Pharma investors own include Intercede Group (IGP), Medpace (MEDP), Regeneron Pharmaceuticals (REGN), Sirius Minerals (SXX), SolGold (SOLG), Petra Diamonds (PDL), Interserve (IRV), Cornerstone Capital Resources (CGP) and Bushveld Minerals (BMN).

Who are N4 Pharma's key executives?

N4 Pharma's management team includes the following people:
  • Mr. Nigel James Theobald, Founder & CEO (Age 55)
  • Mr. Paul Titley, Exec. Director
  • Dr. Andrew Leishman, Consultant

What is N4 Pharma's stock symbol?

N4 Pharma trades on the London Stock Exchange (LON) under the ticker symbol "N4P."

How do I buy shares of N4 Pharma?

Shares of N4P and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is N4 Pharma's stock price today?

One share of N4P stock can currently be purchased for approximately GBX 4.25.

How big of a company is N4 Pharma?

N4 Pharma has a market capitalization of £6.47 million and generates £23,524.00 in revenue each year. N4 Pharma employs 5 workers across the globe.

What is N4 Pharma's official website?

The official website for N4 Pharma is www.n4pharma.com.

How can I contact N4 Pharma?

N4 Pharma's mailing address is Weston House, 1 Bradgate Park View, DERBY, DE73 5UJ, United Kingdom. The company can be reached via phone at +44-1332-690061.

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.